Corpus Intelligence IC Memo — BLUE HILL MEMORIAL HOSPITAL 2026-04-26 10:38 UTC
IC Memo — BLUE HILL MEMORIAL HOSPITAL
Investment Committee Memorandum | ME | 25 beds | Grade C | EBITDA uplift $3.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BLUE HILL MEMORIAL HOSPITAL

CCN 201300 | HANCOCK, ME | 25 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

BLUE HILL MEMORIAL HOSPITAL is a 25-bed suburban community hospital in HANCOCK, ME with $43.0M in net patient revenue and a 7.6% operating margin. The hospital serves a payer mix of 41.5% Medicare, 5.7% Medicaid, and 52.8% commercial.

Thesis: Turnaround. Our ML models identify $3.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 7.6% to 15.0% (+736bps).

Net Revenue HCRIS$43.0M
Current EBITDA COMPUTED$3.3M
Operating Margin COMPUTED7.6%
Occupancy HCRIS31.1%
Revenue / Bed COMPUTED$1.7M
Net-to-Gross HCRIS62.5%
Distress Probability ML56.1%

2. Market Context & Competitive Position

38
ME Hospitals
-8.3%
State Median Margin
21
Comparable Hospitals

ME has 38 Medicare-certified hospitals with a median operating margin of -8.3%. The target's margin of 7.6% places it above the state median. Among 21 size-comparable peers (12-50 beds), the median margin is -6.4%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (12-50), prioritizing same-state peers. 21 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BLUE HILL MEMORIAL HOSPITAL (Target)ME25$43.0M7.6%
REDINGTON-FAIRVIEW GENERAL HOSME25$135.4M-3.6%
THE AROOSTOOK MEDICAL CENTERME34$134.8M-23.5%
LINCOLNHEALTHME25$116.8M-0.9%
WALDO COUNTY GENERAL HOSPITALME25$115.4M-6.4%
FRANKLIN MEMORIAL HOSPITALME46$103.4M-17.3%
STEPHENS MEMORIAL HOSPITAL - CME25$100.5M4.2%
MAINE COAST MEMORIAL HOSPITALME45$98.0M-5.5%
MOUNT DESERT ISLAND HOSPITALME25$74.8M-10.8%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$902K+210bp18mo
Cost to Collect4.5%2.5%$859K+200bp12mo
Denial Rate Reduction12.0%6.5%$851K+198bp12mo
A/R Days Reduction5200.0%3800.0%$523K+122bp9mo
Clean Claim Rate88.0%96.0%$27K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$902K
Cost to Collect
$859K
Denial Rate Reduction
$851K
A/R Days Reduction
$523K
Clean Claim Rate
$27K
Total EBITDA Uplift$3.2M
Current EBITDA$3.3M
+ RCM Uplift+$3.2M
Pro Forma EBITDA$6.4M
Current Margin7.6%
Pro Forma Margin15.0%
WC Released (1x)$1.6M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$5.0M$53.3M10.55x60.2%
Base (11x exit)10.0x11.0x$5.0M$60.2M11.93x64.2%
Bull Case9.0x11.0x$4.5M$72.3M15.92x73.9%
Bull (12x exit)9.0x12.0x$4.5M$80.2M17.66x77.6%
Bear Case11.0x10.0x$5.6M$35.8M6.45x45.2%
Bear (11x exit)11.0x11.0x$5.6M$41.2M7.42x49.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 31.1%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 56.1% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 21 hospitals with 12-50 beds
  • Same-state prioritization (n=22)
  • Comp margins: P25=-10.8% / P50=-6.4% / P75=-0.9%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.